Sai Parenteral's Lists at ₹405, Up 3.06%

Sai Parenteral's Ltd, incorporated in 2001 as a diversified pharmaceutical formulations company operating in branded generic formulations and CDMO segments across therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, and gastroenterology with five manufacturing facilities in Hyderabad and Ongole including TGA-Australia and PIC/S accredited units serving government agencies, hospitals, and pharmaceutical companies while exporting to Australia, New Zealand, Southeast Asia, Middle East, and Africa with 298 employees, made a positive debut on BSE and NSE on Thursday, April 2, 2026. The Sai Parenteral's share price opened at ₹405.00 representing premium of 3.32% from issue price of ₹392.00, touched high of ₹414.00 (up 5.61%) and trading around ₹404.00 (up 3.06%).

Sai Parenteral's Listing Details

Sai Parenteral's launched its IPO at ₹392 per share with minimum investment of 38 shares costing ₹14,896 raising ₹408.79 crore (fresh issue ₹285 crore plus OFS ₹123.79 crore) including ₹122.64 crore from anchor investors. The IPO barely scraped through with subscription of only 1.08 times - retail investors severely undersubscribed at 0.12 times, NII at 2.45 times, QIB at 1.73 times, total applications of 7,938.

First-Day Trading Performance

Listing Price: Sai Parenteral's stock price opened at ₹405.00 representing premium of 3.32% from issue price, touched high of ₹414.00 (up 5.61%) before trading around ₹404.00 (up 3.06%), with VWAP at ₹405.63. The modest listing delivered gains despite weak subscription with turnover of ₹1.89 crore, traded volume of 0.47 lakh shares, delivery of 40.28%, and market capitalisation of ₹1,784.84 crore against pre-IPO market cap of ₹1,731.83 crore.

Growth Drivers and Challenges

Growth Drivers:

Diversified Pharma Portfolio: Branded generic formulations and CDMO business across multiple therapeutic areas with 500+ dossiers spanning injectables, tablets, capsules, liquid orals, and ointments serving diverse customer base.

Strong Financial Growth: Revenue growing from ₹97.03 crore in FY23 to ₹163.74 crore in FY25 (69% growth), PAT growing from ₹4.38 crore to ₹14.43 crore (3x growth), healthy ROCE of 28.92%, EBITDA margin of 24.18%.

Challenges:

Rich Valuations: Post-IPO P/E of 72.19x on higher side compared to industry peers, analyst warns valuation concerns despite growth prospects.

Integration Risks: Planned acquisition of Noumed Pharmaceuticals Australia requiring ₹35.64 crore with execution risks, high borrowings of ₹76.07 crore against net worth.

Utilisation of IPO Proceeds

Capacity Expansion: ₹110.80 crore for capacity expansion and upgradation of manufacturing facilities.

Acquisition: ₹35.64 crore for investment in Singapore subsidiary for proposed acquisition of Noumed Pharmaceuticals Australia.

Working Capital: ₹33.00 crore for working capital requirements.

R&D Centre: ₹18.02 crore for establishment of new R&D centre.

Debt Repayment: ₹14.30 crore for prepayment of outstanding borrowings.

General Corporate Purposes: ₹44.74 crore for general corporate purposes.

Financial Performance

Revenue: ₹89.43 crore for H1 FY26, ₹163.74 crore for FY25, growth from ₹155.18 crore in FY24 and ₹97.03 crore in FY23.

Net Profit: ₹7.76 crore for H1 FY26, ₹14.43 crore in FY25, growth from ₹8.42 crore in FY24 and ₹4.38 crore in FY23, with PAT margin of 8.93%, EBITDA margin of 18.68%, ROE of 16.82%. Investors tracking Sai Parenteral's share price should note strong profitability growth backed by 500+ dossiers and internationally accredited facilities despite high valuation concerns with post-IPO P/E of 72.19x.

Get the latest updates on upcoming IPOs and recent listings.